Targeted delivery of protein drugs by nanocarriers

Materials

Volumn 3, Issue 3, 2010, Pages 1928-1980

  Solaro, Roberto ^a   Chiellini, Federica ^a   Battisti, Antonella ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Nanocarrier; Protein drug; Targeted delivery

Indexed keywords

ENZYMATIC DEGRADATION; HIGH MOLECULAR WEIGHT; NANOCARRIERS; PHARMACOKINETIC PROPERTIES; PROTEIN DRUGS; TARGET ORGANS; TARGETED DELIVERY; THERAPEUTIC EFFECTS;

BIOCHEMISTRY; DISEASES; DRUG INTERACTIONS; LIPOSOMES; TISSUE;

PROTEINS;

EID: 78349294409     PISSN: None     EISSN: 19961944     Source Type: Journal    
DOI: 10.3390/ma3031928     Document Type: Review

References (292)

1. Haag, R.; Kratz, F. Polymer therapeutics: Concept and applications. Angew. Chem. Int. 2006, 45, 1198-1215.
2. Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharm. Rev. 2003, 55, 425-461.
3. Ehrlich, P. Collected Studies in Immunity; Wiley: New York, NY, USA, 1906; p. 442.
4. Crommelin, D.J. Formulation of biotech products, including biopharmaceutical considerations. In Pharmaceutical Biotechnology; Crommelin, D.J., Ed.; Taylor and Francis: London, UK, 1997; pp. 67-94.
5. Salmaso, S.; Bersani, S.; Semenzato, A.; Caliceti, P.J. Nanotechnologies in protein delivery. J. Nanosci. Nanotechol. 2006, 6, 1-18.
6. Lu, Y.; Yang, J.; Sega, E. Issues related to targeted delivery of proteins and peptides. AAPS J. 2006, 8, E466-E478.
7. Violand, B.N.; Siegel, N.R. Peptide and Protein Drug Analysis. In Protein and Peptide Chemical and Physical Stability; Reid, R.E., Ed.; Marcel Dekker: New York, NY, USA, 2000; pp. 257-284.
8. Lee, V.H.L. Peptide and Protein Drug Delivery; Marcel Dekker: New York, NY, USA, 1991.
9. Rabkin, R.; Dahl, D.C. Renal Uptake and Disposal of Proteins and Peptides. In Biological Barriers in Protein Delivery; Audus, K.L., Raub, T.J., Eds.; Plenum Press: New York, NY, USA, 1993; pp. 299-338.
10. Hashida, M.; Nishikawa, M.; Yamashita, F.; Takakura, Y. Cell-specific delivery of genes with glycosylated carriers. Adv. Drug Deliv. Rev. 2001, 52, 187-196.
11. Kotto-Kome, A.C.; Fox, S.E.; Wenge, L.; Bing-Bing, Y.; Christensen, R.D.; Calhoun, D.A. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol. Res. 2004, 50, 55-58.
12. Fujimori, K.; Covell, D.G.; Fletcher, J.E.; Weinstein, J.N. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res. 1989. 49, 5656-5663.
13. Harris, J.M.; Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. 2003, 2, 214-221.
14. Mehwar, R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J. Pharm. Pharm. Sci. 2000, 3, 125-136.
15. Caliceti, P.; Veronese, F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Delivery Rev. 2003, 55, 1261-1277.
16. Canelas, D.A.; Herlihy, K.P.; DeSimone, J.M. Top-down particle fabrication: Control of size and shape for diagnostic imaging and drug delivery. WIREs Nanomed. Nanobiotech. 2009, 1, 391-404.
17. Alexis, F.; Rhee, J.W.; Richie, J.P.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 2008, 26, 74-85.
18. Koo, O.M.; Rubinstein, I.; Onyuksel, H. Role of nanotechnology in drug delivery and imaging: A concise review. Nanomedicine 2005, 1, 193-212.
19. Mundargi, R.C.; Babu, V.R.; Rangaswamy, V.; Patel, P.; Aminabhavi, T.M. Nano/microtechnologies for delivering macromolecular therapeutics using poly(d,l-lactide-coglycolide) and its derivatives. J. Control. Release 2008, 125, 193-209.
20. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55, 329-347.
21. Chiellini, F.; Piras, A.M.; Errico, C.; Chiellini, E. Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomedicine 2008, 3, 367-393.
22. Mishima, K. Biodegradable particle formation for drug and gene delivery using supercritical fluid and dense gas. Adv. Drug Deliv. Rev. 2008, 60, 411-432.
23. Anderson, J.M.; Shive, M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 1997, 28, 5-24.
24. Harashima, H.; Kiwada, H. Liposomal targeting and drug delivery: Kinetic consideration. Adv. Drug Deliv. Rev. 1996, 19, 425-444.
25. Torchilin, V.P. Immobilization of specific proteins on liposome surface: Systems for drug targeting. In Liposome Technology; Gregoriadis, G., Ed.; CRC Press, Inc.: Boca Raton, FL, USA, 1984; Volume 3, pp. 75-94.
26. Crommelin, D.J.A.; Daemen, T.; Scherphof, G.L.; Vingerhoeds, M.H.; Heeremans, J.L.M.; Kluft, C.; Storm, G. Liposomes: Vehicles for the targeted and controlled delivery of peptides and proteins. J. Control. Release 1997, 46, 165-175.
27. Gerasimov, O.V.; Boomer, J.A.; Qualls, M.M.; Thompson, D.H. Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv. Drug Deliv. Rev. 1999, 38, 317-338.
28. Lian, T.; Ho, R.J.Y. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 2001, 90, 667-680.
29. Nobs, L.; Buchegger, F.; Gurny, R.; Allemann, E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci. 2004, 93, 1980-1992.
30. Vasir, J.K.; Reddy, M.K.; Labhasetwar, V.D. Nanosystems in drug targeting: Opportunities and challenges. Curr. Nanosci. 2005, 1, 47-64.
31. Huang, S.-L. Liposomes in ultrasonic drug and gene delivery. Adv. Drug Deliv. Rev. 2008, 60, 1167-1176.
32. Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2004, 56, 1649-1659.
33. Dziubla, T.D.; Muzykantov, V.R. Synthetic carriers for vascular delivery of protein therapeutics. Biotechnol. Gen. Eng. Rev. 2006, 22, 267-298.
34. Roney, C.; Kulkarni, P.; Arora, V.; Antich, P.; Bonte, F.; Wu, A.; Mallikarjuana, N.N.; Manohar, S.; Liang, H.-F.; Kulkarni, A.R.; Sung, H.-W.; Sairam, M.; Aminabhavi, T.M. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J. Control. Release 2005, 108, 193-214.
35. Nahar, M.; Dutta, T.; Murgesan, S.; Asthana, A.; Mishra, D.; Rajkumar, V.; Tare, M.; Saraf, S.; Jain, N.K. Functional polymeric nanoparticles: An efficient and promising tool for active delivery of bioactives. Crit. Rev. Ther. Drug Carrier Syst. 2006, 23, 259-318.
36. Solaro, R.; Chiellini, F. Nanoparticles for the Targeted Delivery of Peptides and Proteins. Handbook of Particulate Drug Delivery; Ravi Kumar, M.N.V., Ed.; American Scientific Publisher: New York, NY, USA 2006 2 193-222
37. Yang, Y.Y.; Wang, Y.; Powell, R.; Chan, P. Polymeric core-shell nanoparticles for therapeutics. Clin. Exp. Pharmacol. Physiol. 2006, 33, 557-562.
38. Husseini, G.A.; Pitt, W.G. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv. Drug Deliv. Rev. 2008, 60, 1137-1152.
39. Solaro, R. Targeted delivery of proteins by nanosized carriers. J. Polym. Sci. A Polym. Chem. 2008, 46, 1-11.
40. Woodle, M.C.; Lasic, D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992, 1113, 171-199.
41. Romberg, B.; Hennink, W.E.; Storm, G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 2008, 25, 55-71.
42. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42, 463-478.
43. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65, 271-284.
44. Hong, R.L.; Huang, C.J.; Tseng, Y.L.; Pang, V.F.; Chen, S.T.; Liu, J.J.; Chang, F.H. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C- 26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial?. Clin. Cancer Res. 1999, 5, 3645-3652.
45. Adiseshaiah, P.P.; Hall, J.B.; McNeil, S.E. Nanomaterial standards for efficacy and toxicity assessment. WIREs Nanobiomed. Nanotechnol. 2009, 2, 99-112.
46. Kong, G.; Braun, R.D.; Dewhirst, M.W. Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size. Cancer Res. 2000, 60, 4440-4445.
47. Maeda, H.; Matsumura, Y.; Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 1989, 6, 193-210.
48. Misselwitz, B.; Platzek, J.; Raduchel, B.; Oellinger, J.J.; Weinmann, H.J. Gadofluorine 8: Initial experience with a new contrast medium for interstitial MR lymphography. Magma 1999, 8, 190-195.
49. Harivardhan Reddy, L.; Sharma, R.K.; Chuttani, K.; Mishra, A.K.; Murthy, R.S. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Control. Release 2005, 105, 185-198.
50. Visser, C.C.; Stevanovitdthom#x0107;, S.; Voorwinden, L.H.; van Bloois, L.; Gaillard, P.J.; Danhof, M.; Crommelin, D.J.A.; de Boer, A.G. Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur. J. Pharm. Sci. 2005, 25, 299-305.
51. Rezler, E.M.; Khan, D.R.; Lauer-Fields, J.; Cudic, M.; Baronas-Lowell, D.; Fields, G.B. Targeted drug delivery utilizing protein-like molecular architecture. J. Am. Chem. Soc. 2007, 129, 4961-4972.
52. Anderson, K.E.; Stevenson, B.R.; Rogers, J.A. Folic acid-PEO-labeled liposomes to improve gastrointestinal absorption of encapsulated agents. J. Control. Release 1999, 60, 189-198.
53. Song, Y.K.; Liu, D.; Maruyama, K.; Takizawa, T. Antibody mediated lung targeting of longcirculating emulsions. J. Pharm. Sci. Technol. 1996, 50, 372-377.
54. Storm, G.; Oussoren, C.; Peeters, P.A.M.; Barenholz, Y.B. Tolerability of liposomes in vivo. Liposome Technology, 2nd ed.; Gregoriadis, G., Ed.; CRC Press, Inc.: Boca Raton, FL, USA 1993 345-383.
55. Bajoria, R.; Sooranna, S.R. Liposome as a drug carrier system: Prospects for safer prescribing during pregnancy: A review. Placenta 1998, 19, 265-287.
56. Bi, R.; Shao, W.; Wang, Q.; Zhang, N. Spray-freeze-dried dry powder inhalation of insulinloaded liposomes for enhanced pulmonary delivery. J. Drug Target. 2008, 16, 639-648.
57. Liguori, L.; Marques, B.; Villegas-Mendez, A.; Rothe, R.; Lenormand, J.-L. Liposomesmediated delivery of pro-apoptotic therapeutic membrane proteins. J. Control. Release 2008, 126, 217-227.
58. Ishida, T.; Harashima, H; Kiwada, H. Liposome clearance. Biosci. Rep. 2002, 22, 197-224.
59. Senior, J.H. Fate and behavior of liposomes in vivo: A review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 1987, 3, 123-193.
60. Fretz, M.M.; Hogset, A.; Koning, G.A.; Jiskoot, W.; Storm, G. Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization. Pharm. Res. 2007, 24, 2040-2047.
61. Scherphof, G.; Roerdink, F.; Waite, M.; Parks, J. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. BBA-Gen. Subjects 1978, 542, 296-307.
62. Dhoot, N.O.; Wheatley, M.A. Microencapsulated liposomes in controlled drug delivery: Strategies to modulate drug release and eliminate the burst effect. J. Pharm. Sci. 2003, 92, 679-689.
63. Veronese, F.M.; Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005, 10, 1451-1458.
64. Owens, D.E., III; Peppas, N.A. Opsonization, biodistribution and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307, 93-102.
65. Van Vlerken, L.E.; Vyas, T.K.; Amiji, M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 2007, 24, 1405-1414.
66. Käsbauer, M.; Lasic, D.D.; Winterhalter, M. Polymer induced fusion and leakage of small unilamellar phospholipids vescicles: Effect of surface grafted polyethylene-glycol in the presence of free PEG. Chem. Phys. Lipids 1997, 86, 153-159.
67. Bedu-Addo, F.K.; Huang, L. Interaction of PEG-phospholipid conjugates with phospholipid implications in liposomal drug delivery. Adv. Drug Deliv. Rev. 1995, 16, 235-247.
68. Lasic, D.D.; Needham, D. The 'stealth' liposome: A prototypical biomaterial. Chem. Rev. 1995, 95, 2601-2628.
69. Mayhew, E.G.; Lasic, D.; Babbar, S.; Martin, F.J. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycolderivatized phospholipid. Int. J. Cancer 1992, 51, 302-309.
70. Sakakibara, T.; Chen, F.-A.; Kida, H.; Kunieda, K.; Cuenca, R.E.; Martin, F.J.; Bankert, R.B. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drugcontaining conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res. 1996, 56, 3743-3746.
71. Judge, A.; McClintock, K.; Phelps, J.R.; MacLachlan, I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 2006, 13, 328-337.
72. Woodle, M.C.; Storm, G.; Newman, M.S.; Jekot, J.J.; Collins, L.R.; Martin, F.J.; Szoka, F.C., Jr. Prolonged systemic delivery of peptide drugs by long-circulating liposomes: Illustration with vasopressin in the brattleboro rat. Pharm. Res. 1992, 9, 260-265.
73. Kedar, E.; Braun, E.; Rutkowski, Y.; Emanuel, N.; Barenholz, Y. Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: Immunomodulatory and anti-tumor activity in mice. J. Immunother. Emphasis Tumor. Immunol. 1994, 16, 115-124.
74. Boerman, O.; Storm, G.; Van Oyen, W.J.G.; Van Bloois, L.; Van Der Meer, J.W.M.; Claessens, R.A.M.J.; Crommelin, D.J.A.; Corstens, F.H.M. Sterically stabilized liposomes labeled with Indium-111 to image focal infection. J. Nucl. Med. 1995, 36, 1639-1644.
75. Yagi, N.; Yano, Y.; Hatanaka, K.; Yokoyama, Y.; Okuno, H. Synthesis and evaluation of a novel lipid-peptide conjugate for functionalized liposome. Bioorg. Med. Chem. Lett. 2007, 17, 2590-2593.
76. Yamada, Y.; Akita, H.; Kamiya, H.; Kogure, K.; Yamamoto, T.; Shinohara, Y.; Yamashita, K.; Kobayashi, H.; Kikuchi, H.; Harashima, H. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim. Biophys. Acta 2008, 1778, 423-432.
77. Kepczytdthom#x0144;ski, M.; Nawalany, K.; Kumorek, M.; Kobierska, A.; Jachimska, B.; Nowakowska, M. Which physical and structural factors of liposome carriers control their drug-loading efficiency? Chem. Phys. Lipids 2008, 155, 7-15.
78. Yu, J.H.; Schaffer, D.V. Advanced targeting strategies for murine retroviral and adeno-associated viral vectors. Adv. Biochem. Eng. Biotech. 2005, 99, 147-167.
79. Kost, T.A.; Condreay, J.P.; Ames, R.S.; Rees, S.; Romanos, M.A. Implementation of BacMam virus gene delivery technology in a drug discovery setting. Drug Discov. Today 2007, 12, 396-403.
80. Eisele, F.; Kuhlmann, J.; Waldmann, H. Synthesis and membrane-binding properties of a characteristic lipopeptide from the membrane-anchoring domain of influenza virus A hemagglutinin. Angew. Chem. Int. Ed. Engl. 2001, 40, 369-373.
81. Daemen, T.; De Mare, A.; Bungener, L.; De Jonge, J.; Huckriede, A.; Wilschut, J. Virosomes for antigen and DNA delivery. Adv. Drug Deliv. Rev. 2005, 57, 451-463.
82. De Jonge, J.; Holtrop, M.; Wilschut, J.; Huckriede, A. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther. 2006, 13, 400-411.
83. Angel, J.; Chaperot, L.; Molens, J.-P.; Mezin, P.; Amacker, M.; Zurbriggen, R.; Grichine, A.; Plumas, J. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine 2007, 25, 3913-3921.
84. Thompson, F.M.; Porter, D.W.; Okitsu, S.L.; Westerfeld, N.; Vogel, D.; Todryk, S.; Poulton, I.; Correa, S.; Hutchings, C.; Berthoud, T.; Dunachie, S.; Andrews, L.; Williams, J.L.; Sinden, R.; Gilbert, S.C.; Pluschke, G.; Zurbriggen, R.; Hill, A.V.S. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 2008, 3, e1493.
85. Morein, B.; Hu, K.-F.; Abusugra, I. Current status and potential application of ISCOMs in veterinary medicine. Adv. Drug Deliv. Rev. 2004, 56, 1367-1382.
86. Bron, R.; Ortiz, A.; Dijkstra, J.; Stegmann, T.; Wilschut, J. Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes). Methods Enzymol. 1993, 220, 313-31.
87. Schoen, P.; Chonn, A.; Cullis, P.R.; Wilschut, J.; Scherrer, P. Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther. 1999, 6, 823-832.
88. Fujii, G. To fuse or not to fuse: The effects of electrostatic interactions, hydrophobic forces, and structural amphiphilicity on protein-mediated membrane destabilization. Adv. Drug Deliv. Rev. 1999, 38, 257-277.
89. Wagner, E. Application of membrane-active peptides for nonviral gene delivery. Adv. Drug Deliv. Rev. 1999, 38, 279-289.
90. Baru, M.; Nahum, O.; Jaaro, H.; Sha'anani, J.; Nur, I. Lysosome-disrupting peptide increases the efficiency of in-vivo gene transfer by liposome-encapsulated DNA. J. Drug Target. 1998, 6, 191-199.
91. Kaneda, Y. Virosomes: Evolution of the liposome as a targeted drug delivery system. Adv. Drug Deliv. Rev. 2000, 43, 197-205.
92. De Jonge, J.; Leenhouts, J.M.; Holtrop, M.; Schoen, P.; Scherrer, P.; Cullis, P.R.; Wilschut, J.; Huckriede, A. Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem. J. 2007, 405, 41-49.
93. Müller, R.H.; Mehnert, W.; Lucks, J.-S.; Schwarz, C.; Zur Mühlen, A.; Meyhers, H.; Freitas, C.; Rühl, D. Solid lipid nanoparticles (SLN): An alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 1995, 41, 62-69.
94. Mukherjee, S.; Ray, S.; Thakur, R.S. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J. Pharm. Sci. 2009, 71, 349-358.
95. Liu, J.; Hu, W.; Chen, H.; Ni, Q.; Xu, H.; Yang, X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int. J. Pharm. 2007, 328, 191-195.
96. Müller, R.H.; Runge, S.A.; Ravelli, V.; Thünemann, A.F.; Mehnert, W.; Souto, E.B. Cyclosporine-loaded solid lipid nanoparticles (SLNtdthom#x00AE;): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 2008, 68, 535-544.
97. Chen, H.; Chang, X.; Du, D.; Liu, W.; Liu, J.; Weng, T.; Yang, Y.; Xu, H.; Yang, H. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J. Control. Release 2006, 110, 296-306.
98. Müller, R.H.; Mäder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery- A review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50, 161-177.
99. Liu, J.; Gong, T.; Wang, C.; Zhong, Z.; Zhang, Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization. Int. J. Pharm. 2007, 340, 153-162.
100. Mehnert, W.; Mäder, K. Solid lipid nanoparticles-Production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47, 165-197.
101. Sjöström, B.; Bergenstahl, B. Preparation of submicron drug particles in lecithin-stabilized o/w emulsions. I. Model studies of the precipitation of cholesteryl acetate. Int. J. Pharm. 1992, 88, 53-62.
102. Schubert, M.A.; Müller-Goymann, C.C. Solvent injection as a new approach for manufacturing lipid nanoparticles-Evaluation of the method and process parameters. Eur. J. Pharm. Biopharm. 2003, 55, 125-131.
103. Hu, F.Q.; Yuan, H.; Zhang, H.H.; Fang, M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm. 2002, 239, 121-128.
104. Trotta, M.; Debernardi, F.; Caputo, O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int. J. Pharm. 2003, 257, 153-160.
105. Puglia, C.; Blasi, P.; Rizza, L.; Schoubben, A.; Bonina, F.; Rossi C.; Ricci, M. Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int. J. Pharm. 2008, 357, 295-304.
106. Joshi, M.D.; Muller, R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 71, 161-172.
107. Salmaso, S.; Bersani, S.; Elvassore, N.; Bertucco, A.; Caliceti, P. Biopharmaceutical characterisation of insulin and recombinant human growth hormone loaded lipid submicron particles produced by supercritical gas. Int. J. Pharm. 2009, 379, 51-58.
108. Caliceti, P.; Salmaso, S.; Elvassore, N.; Bertucco, A. Effective protein release from PEG/PLA nano-particles produced by compressed gas anti-solvent precipitation techniques. J. Control. Release 2004, 94, 195-205.
109. Davies, O.R.; Lewis, A.L.; Whitaker, M.J.; Tai, H.; Shakesheff, K.M.; Howdle, S.M. Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering. Adv. Drug Deliv. Rev. 2008, 60, 373-387
110. Reverchon, E.; Adami, R.; Cardea, S.; Della Porta, G. Supercritical fluids processing of polymers for pharmaceutical and medical applications. J. Supercrit. Fluids 2009, 47, 484-492.
111. Salmaso, S.; Elvassore, N.; Bertucco, A.; Caliceti, P. Production of solid lipid submicron particles for protein delivery using a novel supercritical gas-assisted melting atomization process. J. Pharm. Sci. 2009, 98, 640-650.
112. Lippacher, A.; Müller, R.H.; Mäder, K. Liquid and semisolid SLNtdthom#x2122; dispersions for topical application: Rheological characterization. Eur. J. Pharm. Biopharm. 2004, 58, 561-567.
113. Siekmann, B.; Bunjes, H.; Koch, M.H.J.; Westesen, K. Preparation and structural investigations of colloidal dispersions prepared from cubic monoglyceride-water phases. Int. J. Parm. 2002, 244, 33-43.
114. Liedtke, S.; Wissing, S.; Müller, R.H.; Mäder, K. Influence of high pressure homogenisation equipment on nanodispersions characteristics. Int. J. Pharm. 2000, 196, 183-185.
115. Gasco, M.R. Method for producing solid lipid microspheres having a narrow size distribution. US Pat. No. 5,250,236, 1993.
116. Zur Mühlen, A.; Schwarz, C.; Mehnert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery-Drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45, 149-155.
117. AL-Haj, N.A.; Abdullah, R.; Ibrahim, S.; Bustamam, A. Tamoxifen drug loading solid lipid nanoparticles prepared by hot high pressure homogenization techniques. Am. J. Pharmacol. Toxicol. 2008, 3, 219-224.
118. Harivardhan Reddy, L.; Vivek, K.; Bakshi, N.; Murthy, R.S.R. Tamoxifen citrate loaded solid lipid nanoparticles (SLNtdthom#x2122;): Preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm. Dev. Technol. 2006, 11, 167-177.
119. Almeida, A.J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 2007, 59, 478-490.
120. Almeida, A.J.; Runge, S.; Müller, R.H. Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters. Int. J. Pharm. 1997, 149, 255-265.
121. Hu, F.Q.; Hong, Y.; Yuan, H. Preparation and characterization of solid lipid nanoparticles containing peptide. Int. J. Pharm. 2004, 273, 29-35.
122. Li, S.; Zhao, B.; Wang, F.; Wang, M.; Xie, S.; Wang, S.; Han, C.; Zhu, L.; Zhou, W. Yak interferon-alpha loaded solid lipid nanoparticles for controlled release. Res. Vet. Sci. 2010, 88, 148-153.
123. Gualbert, J.; Shahgaldian, P.; Coleman, A.W. Interactions of amphiphilic calyx[4]arene-based solid lipid nanoparticles with bovine serum albumin. Int. J. Pharm. 2003, 257, 69-73.
124. Olbrich, C.; Geßner, A.; Kayser, O.; Müller, R.H. Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target. 2002, 10, 387-396.
125. Penkler, L.; Müller, R.H.; Runge, S.; Ravelli, V. Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. US Pat. No. 6,551,619, 2003.
126. Ugazio, E.; Cavalli, R.; Gasco, M.R. Incorporation of cyclosporine A in solid lipid nanoparticles (SLN). Int. J. Pharm. 2002, 24, 341-344.
127. Cavalli, R.; Bocca, C.; Miglietta, A.; Caputo, O.; Gasco, M.R. Albumin adsorption on stealth and non-stealth solid lipid nanoparticles. STP Pharma. Sci. 1999, 9, 183-189.
128. Garcßa-Fuentes, M.; Torres, D.; Alonso, M.J. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf. B Biointerf. 2002, 27, 159-168.
129. Zhang, N.; Ping, Q.; Huang, G.; Xu, W.; Cheng, Y.; Han, X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm. 2006, 327, 153-159.
130. Caliceti, P.; Brossa, A.; Salmaso, S.; Bersani, S.; Elvassore, N.; Bertucco, A. Preparation of protein loaded solid lipid nano-particles by compressed fluid process. Proc. Int. Symp. Control. Rel. Bioact. Mater. 2006, 23, 383.
131. Morel, S.; Gasco, M.R.; Cavalli, R. Incorporation in lipospheres of [D-Trp-6] LHRH. Int. J. Pharm. 1994, 105, R1-R3.
132. Videira, M.; Azevedo, A.F.; Almeida, A.J. Entrapment of a high molecular weight protein into solid lipid nanoparticles. Proc. 2nd World Meeting APV/APGI, Paris, May 1998; pp. 629-630.
133. Morel, S.; Ugazio, E.; Cavalli, R.; Gasco, M.R. Thymopentin in solid lipid nanoparticles. Int. J. Pharm. 1996, 132, 259-261.
134. Schöler, N.; Hahn, H., Müller, R.H.; Liesenfeld, O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm. 2002, 231, 167-176.
135. Wang, Y.; Wu, W. In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages. Drug Deliv. 2006, 13, 189-192.
136. Garcia-Fuentes, M.; Torres, D.; Alonso, M.J. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int. J. Pharm. 2005, 296, 122-132.
137. Constantinides, P.P.; Scalart, J.P.; Lancastar, S.; Marcello, J.; Marks, G.; Ellens, H.; Smith, P.L. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm. Res. 1994, 11, 1385-1390.
138. Vauthier, C.; Bouchemal, K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm. Res. 2009, 26, 1025-1058.
139. Qiu, L.Y.; Bae, Y.H. Polymer architecture and drug delivery. Pharm. Res. 2006, 23, 1-30
140. Vauthier, C.; Labarre, D. Modular biomimetic drug delivery systems. J. Drug Deliv. Sci. Technol. 2008, 18, 59-68
141. van de Weert, M.; Hennink, W.E.; Jiskoot, W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 2000, 17, 1159-1167
142. Cheng, J.; Teply, B.A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F.X.; Levy-Nissenbaum, E.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28, 869-876.
143. Duan, J.; Zhang, Y.; Chen, W.; Shen, C.; Liao, M.; Pan, Y.; Wang, J.; Deng, X.; Zhao, J. Cationic polybutyl cyanoacrylate nanoparticles for DNA delivery. J. Biomed. Biotechnol. 2009, 149254.
144. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70, 1-20.
145. Rytting, E.; Nguyen, J.; Wang, X.; Kissel, T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2008, 5, 629-639.
146. Akin, D.; Sturgis, J.; Ragheb, K.; Sherman, D.; Burkholder, K.; Robinson, J.P.; Bhunia, A.K.; Mohammed, S.; Bashir, R. Bacteria-mediated delivery of nanoparticles and cargo into cells. Nat. Nanotech. 2007, 2, 441-449.
147. Minigo, G.; Scholzen, A.; Tang, C.K.; Hanley, J.C.; Kalkanidis, M.; Pietersz, G.A.; Apostolopoulos, V.; Plebanski, M. Poly-L-lysine-coated nanoparticles: A potent delivery system to enhance DNA vaccine efficacy. Vaccine 2007, 25, 1316-1327.
148. Hasadsri, L.; Kreuter, J.; Hattori, H.; Iwasaki, T.; George, J.M. Functional protein delivery into neurons using polymeric nanoparticles. J. Biol. Chem. 2009, 284, 6972-6981.
149. Weiss, C.K.; Kohnle, M.-V.; Landfester, K.; Hauk, T.; Fischer, D.; Schmitz-Wienke, J.; Mailänder, V. The first step into the brain: Uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation. Chem. Med. Chem. 2008, 3, 1395-1403.
150. Vauthier, C.; Dubernet, C.; Chauvierre, C.; Brigger, I.; Couvreur, P. Drug delivery to resistant tumors: The potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Release 2003, 93, 151-160.
151. Stella, B.; Arpicco, S.; Peracchia, M.T.; Desmaele, D.; Hoebeke, J.; Renoir, M.; D'Angelo, J.; Cattel, L.; Couvreur, P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 2000, 89, 1452-1464.
152. Kim, H.R.; Andrieux, K.; Gil, S.; Taverna, M.; Chacun, H.; Desmaele, D.; Taran, F.; Georgin, D.; Couvreur, P. Translocation of poly(ethylene glycol-co-hexadecyl) cyanoacrylate nanoparticles into rat brain endothelial cells: Role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 2007, 8, 793-799.
153. Fang, C.; Shi, B.; Pei, Y.-Y.; Hong, M.-H.; Wu, J.; Chen, H.-Z. In vivo tumor targeting of tumor necrosis factor-tdthom#x03B1;-loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci. 2006, 27, 27-36.
154. Li, Y.-P.; Pei, Y.-Y.; Zhou, Z.-H.; Zhang, X.-Y.; Gu, Z.-H.; Ding, J.; Zhou, J.-J.; Gao, X.-J.; Zhu, J.-H. Stealth polycyanoacrylate nanoparticles as tumor necrosis Factor-tdthom#x03B1; carriers: Pharmacokinetics and anti-tumor effects. Biol. Pharm. Bull. 2001, 24, 662-665.
155. Calvo, P.; Gouritin, B.; Brigger, I.; Lasmezas, C.; Deslys, J.-P.; Williams, A.; Andreux, J.P.; Dormont, D.; Couvreur, P. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J. Neurosci. Methods 2001, 111, 151-155.
156. Lukyanov, A.N.; Torchilin, V. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv. Drug Deliv. Rev. 2004, 56, 1273-1289.
157. Bisht, S.; Feldmann, G.; Soni, S.; Ravi, R.; Karikar, C.; Maitra, A.; Maitra, A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J. Nanobiotechnol. 2007, 5, doi:10.1186/1477-3155-5-3.
158. Kim, J.H.; Park, K.; Nam, H.Y.; Lee, S.; Kim, K.; Kwon, I.C. Polymers for bioimaging. Prog. Polym. Sci. 2007, 32, 1031-1053.
159. Kim, K.; Lee, M.; Park, H.; Kim, J.-H.; Kim, S.; Chung, H.; Choi, K.; Kim, I.-S.; Seong, B.L.; Kwon, I.C. Cell-permeable and biocompatible polymeric nanoparticles for apoptosis imaging. J. Am. Chem. Soc. 2006, 128, 3490-3491.
160. Bala, I.; Hariharan, S.; Ravi Kumar, M.N.V. PLGA nanoparticles in drug delivery: The state of the art. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21, 387-422.
161. Vasir, J.K.; Labhasetwar, V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 2007, 59, 718-728.
162. Freitas, S.; Hielscher, G.; Merkle, H.P.; Gander, B. A fast and simple method for producing biodegradable nanospheres. Eur. Cell. Mater. 2004, 7, 28.
163. Damgé, C.; Maincent, P.; Ubrich, N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release 2007, 117, 163-170.
164. Cui, F.; Shi, K.; Zhang, L.; Tao, A.; Kawashima, Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J. Control. Release 2006, 114, 242-250.
165. Vila, A.; Sànchez, A.; Tobìo, M.; Calvo, P.; Alonso, M.J. Design of biodegradable particles for protein delivery. J. Control. Release 2002, 78, 15-24.
166. Dziubla, T.D.; Karim, A.; Muzykantov, V.R. Polymer nanocarriers protecting active enzyme cargo against proteolysis. J. Control. Release 2005, 102, 427-439.
167. Tobio, M.; Sanchez, A.; Vila, A.; Soriano, I.; Evora, C.; Vila-Jato, J.L.; Alonso, M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloid. Surfaces B Biointerf. 2000, 18, 315-323.
168. Vila, A.; Sanchez, A.; Evora, C.; I. Soriano, I.; McCallion, O.; Alonso, M.J. PLA-PEG particles as nasal protein carriers: The influence of the particle size. Int. J. Pharm. 2005, 292, 43-52.
169. Simone, E.A.; Dziubla, T.D.; Colon-Gonzalez, F.; Discher, D.E.; Muzykantov, V.R. Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules 2007, 8, 3914-3921.
170. Simone, E.A.; Dziubla, T.D.; Discher, D.E.; Muzykantov, V.R. Filamentous polymer nanocarriers of tunable stiffness that encapsulate the therapeutic enzyme catalase. Biomacromolecules 2009, 10, 1324-1330.
171. Chiellini, F.; Bartoli, C.; Dinucci, D.; Piras, A.M.; Anderson, R.; Croucher, T. Bioeliminable polymeric nanoparticles for proteic drug delivery. Int. J. Pharm. 2007, 343, 90-97.
172. Coué, G.; Feijen, J.; Engbersen, J.F.J. Development of biodegradable poly(amidoamine)s for protein delivery. J. Control. Release 2008, 132, e2-e3.
173. Akagi, T.; Wang, X.; Uto, T.; Baba, M.; Akashi, M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 2007, 28, 3427-3436.
174. Chen, F.; Zhang, Z.-R.; Yuan, F.; Qin, X.; Wang, M.; Huang, Y. In vitro and in vivo study of Ntrimethyl chitosan nanoparticles for oral protein delivery. Int. J. Pharm. 2008, 349, 226-233.
175. Sarmento, B.; Ribeiro, A.; Veiga, F.; Sampaio, P.; Neufeld, R.; Ferreira, D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res. 2007, 24, 2198-2206.
176. Thakkar, H.; Sharma, R.K.; Mishra, A.K.; Chuttani, K.; Murthy, R.R. Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS Pharm. Sci. Tech. 2005, 6, E65-E73.
177. Chiellini, E.; Chiellini, E.E.; Chiellini, F.; Solaro, R. Targeted administration of proteic drugs. I. preparation of polymeric nanoparticles. J. Bioact. Compat. Polym. 2001, 16, 441-465.
178. Chiellini, E.E.; Chiellini, F.; Solaro, R. Bioerodible polymeric nanoparticles for targeted administration of proteic drugs. J. Nanosci. Nanotechnol. 2006, 6, 3040-3047.
179. Solaro, R.; Chiellini, F.; Signori, F.; Fiumi, C.; Bizzarri, R.; Chiellini, E. Nanoparticle systems for the targeted release of active principles of proteic nature. J. Mat. Sci. Mater. Med. 2003, 14, 705-711.
180. Merkel, T.J.; Herlihy, K.P.; Nunes, J.; Orgel, R.M.; Rolland, J.P.; DeSimone, J.M. Scalable, shape-specific, top-down fabrication methods for the synthesis of engineered colloidal particles. Langmuir 2010, doi: 10.1021/la903890h.
181. Kelly, J.Y.; Desimone, J.M. Shape-specific, monodisperse nano-molding of protein particles. J. Am. Chem. Soc. 2008, 130, 5438-5439.
182. Yu-Su, S.Y.; Thomas, D.R.; Alford, J.E.; LaRue, I.; Pitsikalis, M.; Hadjichristidis, N.; DeSimone, J.M.; Dobrynin, A.V.; S. Sheiko, S.S. Molding block copolymer micelles: A framework for molding of discrete objects on surfaces. Langmuir 2008, 24, 12671-12679.
183. Zhang, H.; Nunes, J.K.; Gratton, S.E.A.; Herlihy, K.P.; Pohlhaus, P.D.; DeSimone, J.M. Fabrication of multiphasic and regio-specifically functionalized PRINTtdthom#x00AE; particles of controlled size and shape. New J. Phys. 2009, 11, 075018.
184. Anton, N.; Saulnier, P.; Gaillard, C.; Porcher, E.; Vrignaud, S.; Benoit, J.-P. Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules. Langmuir 2009, 25, 11413-11419.
185. Daoud-Mahammed, S.; Ringard-Lefebvre, C.; Razzouq, N.; Rosilio, V.; Gillet, B.; Couvreur, P.; Amiel, C.; Gref, R. Spontaneous association of hydrophobized dextran and poly-tdthom#x03B2;-cyclodextrin into nanoassemblies. Formation and interaction with a hydrophobic drug. J. Colloid Interf. Sci. 2007, 307, 83-93.
186. Nishikawa, T.; Akiyoshi, K.; Sunamoto, J. Supramolecular assembly between nanoparticles of hydrophobized polysaccharide and soluble protein complexation between the self-aggregate of cholesterol-bearing pullulan and tdthom#x03B1;-chymotrypsin. Macromolecules 1994, 27, 7654-7659.
187. Akiyoshi, K.; Nishikawa, T.; Mitsui, Y.; Miyata, T.; Kodama, M.; Sunamoto, J. Self-assembly of polymer amphiphiles: Thermodynamics of complexation between bovine serum albumin and self-aggregate of cholesterol-bearing pullulan. Colloids Surf. A Physicochem. Eng. Asp. 1996, 112, 91-95.
188. Chattopadhyay, P.; Gupta R.B. Protein nanoparticles formation by supercritical antisolvent with enhanced mass transfer. AIChE J. 2002, 48, 235-244
189. 2 system for nanoparticle preparation of indomethacin. Int. J. Pharm. 2010, 386, 243-248.
190. Cooper, A.I. Polymer synthesis and processing using supercritical carbon dioxide. J. Mater. Chem. 2000, 10, 207-234
191. Schrama, D.; Reisfeld, R.A.; Becker, J.C. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5, 147-159.
192. Yamada, Y.; Akita, H.; Kogure, K.; Kamiya, H.; Harashima, H. Mitochondrial drug delivery and mitochondrial disease therapy-An approach to liposome-based delivery targeted to mitochondria. Mitochondrion 2007, 7, 63-71.
193. Tanaka, M.; Borgeld, H.M.; Zhang, J.; Muramatsu, S.; Gong, J.S.; Yoneda, M.; Maruyama, W.; Naoi, M.; Ibi, T.; Sahashi, K.; Shamoto, M.; Fuku, N.; Kurata, M.; Yamada, Y.; Nishizawa, K.; Akao, Y.; Ohishi, N.; Miyabayashi, S.; Umemoto, H.; Muramatsu, T.; Furukawa, K.; Kikuchi, A.; Nakano, I.; Ozawa, K.; Yagi, K. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J. Biomed. Sci. 2002, 9, 534-541.
194. Futaki, S. Arginine-rich peptides: Potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int. J. Pharm. 2002, 245, 1-7.
195. Rapoport, M.; Lorberboum-Galski, H. TAT-based drug delivery system-New directions in protein delivery for new hopes? Expert Opin. Drug Deliv. 2009, 6, 453-463.
196. Schwarze, S.R.; Hruska, K.A.; Dowdy, S.F. Protein transduction: Unrestricted delivery into all cells? Trends Cell Biol. 2002, 10, 290-295.
197. Shokolenko, I.N.; Alexeyev, M.F.; LeDoux, S.P.; Wilson, G.L. TAT-mediated protein transduction and targeted delivery of fusion proteins into mitochondria of breast cancer cells. DNA Repair (Amst) 2005, 4, 511-518.
198. Middlebrook, J.L.; Dorland, R.B. Bacterial toxins: Cellular mechanisms of action. Microbiol. Rev. 1984, 48, 199-221.
199. Bade, S.; Rummel, A.; Reisinger, C.; Karnath, T.; Ahnert-Hilger, G.; Bigalke, H.; Binz, T. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J. Neurochem. 2004, 91, 1461-1472.
200. Lu, Y.; Adams, R.; Sun, W.; Lee, I.; Debromilskaya, I.; Drachman, D.B. Targeting of viral vectors to motor neurons by botulinum toxin binding domain to treat ALS. Mol. Ther. 2006, 13, S347.
201. Chen, S.; Barbieri, J.T. Engineering botulinum neurotoxin to extend therapeutic intervention. Proc. Natl. Acad. Sci. USA 2009, 106, 9180-9184.
202. Foster, K.A. Engeneered toxins: New therapeutics. Toxicon 2009, 54, 587-592.
203. Sokoloff, A.V.; Wong, S.C.; Ludtke, J.J.; Sebestyen M.G.; Subbotin, V.M.; Zhang, G.; Budker, T.; Bachhuber, M.; Sumita, Y.; Wolff, J.A. A new peptide ligand that targets particles and heterologous proteins to hepatocytes in vivo. Mol. Ther. 2003, 8, 867-872.
204. Wong, S.C.; Wakefield, D.; Klein, J.; Monahan, S.D.; Rozema, D.B.; Lewis, D.L.; Higgs, L.; Ludtke, J.J.; Sokoloff, A.V.; Wolff, J.A. Hepatocyte targeting of nucleic acid complexes and liposomes by a T7 phage p17 peptide. Mol. Pharm. 2006, 3, 386-397.
205. Sharma, S.K.; Pedley, R.B.; Bhatia, J.; Boxer, G.M.; El-Emir, E.; Qureshi, U.; Tolner, B.; Lowe, H.; Michael, N.P.; Minton, N.; Begent, R.H.J.; Chester, K.A. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin. Cancer Res. 2005, 11, 814-825.
206. Williams, A.S.; Camilleri, J.P.; Goodfellow, R.M.; Williams, B.D. A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigeninduced arthritis. Br. J. Rheumatol. 1996, 35, 719-724.
207. Chazov, E.I.; Alexeev, A.V.; Antonov, A.S.; Koteliansky, V.E.; Leytin, V.L.; Ljubimova, A.V.; Repin, V.S.; Sviridov, D.D.; Torchilin V.P.; Smirnov, V.N. Endothelial cell culture on fibrillar collagen: Model to study plateled adhesion and liposome targeting to intercellular collagen matrix. Procl. Natl. Acad. Sci. USA 1981, 78, 5603-5607.
208. Himber, J.; Sallee, V.L.; Andermann, G.; Bouzoubaa, M.; Leclerc, G.;, De Santis, L. Effects of topically applied falintolol: A new beta-adrenergic antagonist for treatment of glaucoma. J. Ocul. Pharmacol. Ther. 1987, 3, 111-120.
209. Ma, L.; Wu, X.; Ling-Ling, E.; Wang, D.-S.; Liu, H.-C. The transmembrane transport of metformin by osteoblasts from rat mandible. Arch. Oral Biol. 2009, 54, 951-962.
210. Jenning, V.; Gysler, A.; Schäfer-Korting, M.; Gohla, S.H. Vitamin A loaded solid lipid nanoparticles for topical use: Occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 2000, 49, 211-218.
211. Santos Maia, C.; Mehnert, W; Schäfer-Korting, M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int. J. Pharm. 2000, 196, 165-167.
212. Bhaskar, K.; Anbu, J.; Ravichandiran, V.; Venkateswarlu, V.; Madhusudan Rao, Y. Lipid nanoparticles for transdermal delivery of flurbiprofen: Formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis. 2009, 8, doi:10.1186/1476-511X-8-6.
213. Seymour, L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9, 135-187.
214. Matsumura Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 46, 6387-6392.
215. Maeda, H.; Matsumura, Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 1989, 6, 193-210.
216. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65, 271-284.
217. Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 2001, 74, 47-61.
218. Greish, K.; Iyer, A.K.; Fan, J.; Maeda, H. Enhanced permeability and retention (EPR) effect and tumor selective delivery of anticancer drugs. In Delivery of Protein and Peptide Drugs to Cancer; Torchilin, V.P., Ed.; Imperial College Press: London, UK, 2006; pp. 37-52.
219. Maeda, H.; Greish, K.; Fang, J. The EPR effect and polymeric drugs: A paradigm shift for cancer chemotherapy in the 21st century. Adv. Polym. Sci. 2006, 193, 103-121.
220. Greish, K. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J. Drug Target. 2007, 15, 457-464.
221. Gabizon, A.A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992, 52, 891-896.
222. Jun, Y.J.; Kim, J.I.; Jun, M.J.; Sohn, Y.S. Selective tumor targeting by enhanced permeability and retention effect. Synthesis and antitumor activity of polyphosphazene-platinum (II) conjugates. J. Inorg. Biochem. 2005, 99, 1593-1601.
223. Palframan, R.; Vugle, A.; Moore, A.; Baker, M.; Lightwood, D.; Nesbitt, A.; Foulkes, R.; Gozzard, N. Certolizumab pegol and adalimumab accumulation in the inflammed paws of mice with collagen-induced arthritis compared to noninflammed tissue in vivo biofluorescence imaging of Alexa 680-labeled antibodies. Clin. Immunol. 2007, 123, S170.
224. Seow, W.Y.; Xue, J.M.; Yang, Y.-Y. Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles. Biomaterials 2007, 28, 1730-1740.
225. Soppimath, K.S.; Liu, L.-H.; Seow, W.Y.; Liu, S.-Q.; Powell, R.; Chan, P.; Yang, Y.-Y. Multifunctional core/shell nanoparticles self-assembled from pH-induced thermosensitive polymers for targeted intracellular anticancer drug delivery. Adv. Funct. Mater. 2007, 17, 355-362.
226. Dai, J.; Nagai, T.; Wang, X.; Zhang, T.; Meng, M.; Zhang, Q. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int. J. Pharm. 2004, 280, 229-240.
227. Kawashima, Y.; Niwa, T.; Handa, T.; Takeuchi, H.; lwamoto, T.; Itoh, K. Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method. J. Pharm. Sci. 1989, 78, 68-72.
228. El-Sayed, M.E.H.; Hoffman, A.S.; Stayton, P.S. Smart polymeric carriers for enhanced intracellular delivery of therapeutic macromolecules. Expert Opin. Biol. Ther. 2005, 5, 23-32.
229. Freeman, R.W.; Arrott, A.; Watson, J.H.L. Magnetism in medicine. J. Appl. Phys. 1960, 31, S404.
230. Portet, D.; Denizot, B.; Rump, E.; Lejeune, J.-J.; Jallet, P. Nonpolymeric coatings of iron oxide colloids for biological use as magnetic resonance imaging contrast agents. J. Colloid Interface Sci. 2001, 238, 37-42.
231. Gupta, A.K.; Wells, S. Surface-modified superparamagnetic nanoparticles for drug delivery: Preparation, characterization, and cytotoxicity studies. IEEE Trans. Nanobiosci. 2004, 3, 66-73.
232. Ström, V.; Hultenby, K.; Grüttner, C.; Teller, J.; Xu, B.; Holgersson, J. A novel and rapid method for quantification of magnetic nanoparticle-cell interactions using a desktop susceptometer. Nanotechnology 2004, 15, 457-466.
233. Neuberger, T.; Schöpf, B.; Hofmann, H.; Hofmann, M.; von Rechenberg, B. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J. Magn. Magn. Mater. 2005, 293, 483-496.
234. Dobson, J. Magnetic nanoparticles for drug delivery. Drug Dev. Res. 2006, 67, 55-60.
235. Alexiou, C.; Schmid, R.J.; Jurgons, R.; Kremer, M.; Wanner, G.; Bergemann, G.; Huenges, E.; Nawroth, T.; Arnold, W.; Parak, F.G. Targeting cancer cells: Magnetic nanoparticles as drug carriers. Eur. Biophys. J. 2006, 35, 446-450.
236. Alexiou, C.; Jurgons, R.; Schmid, R.J.; Bergemann, G.; Henke, J.; Erhardt, W.; Huenges, E.; Parak, F.G. Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent Mitoxantrone after locoregional cancer treatment. J. Drug Target. 2003, 11, 139-149.
237. Jurgons, R.; Seliger, C.; Hilpert, A.; Trahms, L.; Odenbach, S.; Alexiou, C. Drug loaded magnetic nanoparticles for cancer therapy. J. Phys.: Condens. Matter 2006, 18, S2893-S2902.
238. Torchilin, V.P.; Paptov, M.I.; Orekova, N.M.; Belyaev, A.A.; Petrov, A.D.; Ragimov, S.E. Magnetically driven thrombolytic preparation containing immobilized streptokinase-targeted transport and action. Haemostasis 1988, 18, 113-116.
239. Mikhaylova, M.; Kim, D.K.; Berry, C.C.; Zagorodni, A.; Toprak, M.; Curtis, A.S.G.; Muhammed, M. BSA immobilization on amine-functionalized superparamagnetic iron oxide nanoparticles. Chem. Mater. 2004, 16, 2344-2354.
240. Xu, L.; Kim, M.-J.; Kim, K.-D.; Choa, Y.-H.; Kim, H.-T. Surface modified Fe3O4 nanoparticles as a protein delivery vehicle. Colloid Surf. A-Physicochem. Eng. Asp. 2009, 350, 8-12.
241. Kohler, N.; Fryxell, G.E.; Zhang, M.Q. A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J. Am. Chem. Soc. 2004, 126, 7206-7211.
242. Lecommandoux, S.; Sandre, O.; Chécot, F.; Perzynski, R. Smart hybrid magnetic self-assembled micelles and hollow capsules. Prog. Solid State Chem. 2006, 34, 171-179.
243. Mastrobattista, E.; Koning, G.A.; Storm, G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv. Drug Deliv. Rev. 1999, 40, 103-127.
244. Farokhzad, O.C.; Jon, S.; Khademhosseini, A.; Tran, T.-N.T.; LaVan, D.A.; Langer, R. Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res. 2004, 74, 7668-7672.
245. Farokhzad, O.C.; Khademhosseini, A.; Jon, S.; Hermmann, A.; Cheng, J.; Chin, C.; Kiselyuk, A.; Teply, B.; Eng, G.; Langer, R. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal. Chem. 2005, 77, 5453-5459.
246. Huang, Y.-F.; Kim, Y.; Meng, L.; Tan, W. Assembly of aptamer conjugates as molecular tools in therapeutics. Chem. Today 2009, 27, 52-54.
247. Vivès, E. Present and future of cell-penetrating peptide mediated delivery systems: "Is the Trojan horse too wild to go only to Troy?" J. Control. Release 2005, 109, 77-85.
248. Vivès, E.; Schmidt, J.; Pèlegrin, A. Cell-penetrating and cell-targeting peptides in drug delivery. BBA-Rev. Cancer 2008, 1786, 126-138.
249. Shin, S.U.; Friden, P.; Moran, M.; Olson, T.; Kang, Y.S.; Pardridge, W.M.; Morrison, S.L. Transferrin-antibody fusion proteins are effective in brain targeting. Proc. Natl. Acad. Sci. USA 1995, 92, 2820-2824.
250. Quan, C.-Y.; Chang, C.; Wei, H.; Chen, C.-S.; Xu, X.-D.; Cheng, S.-X.; Zhang, X.Z.; Zhuo, R.X. Dual targeting of a thermosensitive nanogel conjugated with transferrin and RGD-containing peptide for effective cell uptake and drug release. Nanotechnology, 2009, 20, 335101.
251. Minko, T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv. Drug Deliv. Rev. 2004, 56, 491-509.
252. Yamazaki, N.; Kojima, S.; Bovin, N.V.; André, S.; Gabius, S.; Gabius, H.-J. Endogenous lectins as targets for drug delivery. Adv. Drug Deliv. Rev. 2000, 43, 225-244.
253. Tulsani, N.B.; Kumar, A.; Pasha, Q.; Kumar, H.; Sarma, U.P. Immobilization of hormones for drug targeting. Artif. Cells Blood Substit. Immobil. Biotechnol. 2000, 28, 503-519.
254. Daniels, T.R.; Delgado, T.; Helguera, G.; Penichet, M.L. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 2006, 121, 159-176.
255. Sudimak, J.; Lee, R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 2000, 41, 147-162.
256. Andresen, T.L.; Jensen, S.S.; Jorgensen, K. Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog. Lipid Res. 2004, 44, 68-97.
257. Barenholz, Y. Liposome application: Problems and prospects. Curr. Opin. Colloid Interface Sci. 2000, 6, 66-77.
258. Chowdhury, P.S.; Wu, R. Tailor-made antibody therapeutics. Methods 2005, 36, 11-24.
259. Van Osdol, W.; Fujimori, K.; Weinstein, J.N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a "binding site barrier". Cancer Res. 1991, 51, 4776-4784.
260. Fischman, A.J.; Babich, J.W.; Strauss, H.W. A ticket to ride: Peptide radiopharmaceuticals. J. Nucl. Med. 1993, 34, 2253-2263.
261. Wu, D.; Yang, J.; Pardridge, W.M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 1997, 100, 1804-1812.
262. Cegnar, M.; Kocbek, P.; Obermajer, N.; Kos, J.; Kristl, J. Immunonanoparticles for targeting and delivery of protein drugs into tumour cells. J. Control. Release 2008, 132, e60-e61.
263. Messerschmidt, S.K.E.; Musyanovych, A.; Altvater, M.; Scheurich, P.; Pfizenmaier, K.; Landfester, K.; Kontermann, R.E. Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells. J. Control. Release 2009, 137, 69-77.
264. Kontermann, R.E. Immunoliposomes for cancer therapy. Curr. Opin. Mol. Ther. 2006, 8, 39-45.
265. Yamada, T.; Iwasaki, Y.; Tada, H.; Iwabuki.; H, Chuah, M.K.; VandenDriessche, T.; Fukuda, H.; Kondo, A.; Ueda, M.; Seno, M.; Tanizawa, K.; Kuroda, S. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat. Biotechnol. 2003, 21, 885-890.
266. Kurata, N.; Shishido, T.; Muraoka, M.; Tanaka, T.; Ogino, C.; Fukuda, H.; Kondo, A. Specific protein delivery to target cells by antibody-displaying bionanocapsules. J. Biochem. 2008, 144, 701-707.
267. Desnick, R.J.; Schuchman E.H. Enzyme replacement and enhancementtherapies: Lessons from lysosomal disorders. Nat. Rev. Genet. 2002, 3, 954-966.
268. Garnacho, C.; Dhami, R.; Simone, E.; Dziubla, T.; Leferovich, J.; Schuchman, E.H.; Muzykantov, V.; Muro, S. Delivery of acid sphingomyelinase in normal and Niemann-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J. Pharm. Exp. Ther. 2008, 325, 400-408.
269. Muro, S.; Cui, X.; Gajewski, C.; Murciano, J.C.; Muzykantov, V.R.; Koval, M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am. J. Physiol. Cell Physiol. 2003, 285, C1339-C1347.
270. Muro, S.; Gajewski, C.; Koval, M.; Muzykantov, V.R. ICAM-1 recycling in endothelial cells: A novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood 2005, 105, 650-658.
271. Muro, S.; Dziubla, T.; Qiu, W.; Leferovich, J.; Cui, X.; Berk, E.; Muzykantov, V.R. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J. Pharmacol. Exp. Ther. 2006, 317, 1161-1169.
272. Muro, S.; Mateescu, M.; Gajewski, C.; Robinson, M.; Muzykantov, V.R.; Koval, M. Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am. J. Physiol. Lung Cell Mol. Physiol. 2006, 290, L809-L817.
273. Garnacho, C.; Albelda, S.M.; Muzykantov, V.R.; Muro, S. Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J. Control. Release 2008, 130, 226-233.
274. Dhar, S.; Gu, F.X.; Langer, R.; Farokhzad, O.C.; Lippard, S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA 2008, 105, 17356-17361.
275. Terada, T.; Mizobata, M.; Kawakami, S.; Yamashita, F.; Hashida, M. Optimization of tumorselective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. J. Control. Release 2007, 119, 262-270.
276. Kogure, K.; Moriguchi, R.; Sasaki, K.; Ueno, M.; Futaki, S.; Harashima, H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J. Control. Release 2004, 98, 317-323.
277. Khalil, I.A.; Kogure, K.; Futaki, S.; Harashima, H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem. 2006, 281, 3544-3551.
278. Suzuki, R.; Yamada, Y.; Harashima, H. Efficient cytoplasmic protein delivery by means of a multifunctional envelope-type nano device. Biol. Pharm. Bull. 2007, 30, 758-762
279. Demirgöz, D.; Pangburn, T.O.; Davis, K.P.; Lee, S.; Bates, F.S.; Kokkoli, E. PR_b-Targeted delivery of tumor necrosis factor-tdthom#x03B1; by polymersomes for the treatment of prostate cancer. Soft Matter 2009, 5, 2011-2019.
280. Schwarze, S.R.; Dowdy, S.F. In vivo protein transduction; intracellular delivery of biologically active proteins, compounds and DNA. Trend Pharmacol. Sci. 2000, 21, 45-48.
281. Nam, Y.S.; Park, J.Y.; Han, S.-H.; Chang, I.-S. Intracellular drug delivery using poly(D,L-lactideco-glycolide) nanoparticles derivatized with a peptide from a transcriptional activator protein of HIV-1. Biotechnol. Lett. 2002, 24, 2093-2098.
282. Huwyler, J.; Wu, D.; Pardridge, W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA 1996, 93, 14164-14169.
283. Li, H.; Qian, Z.M. Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 2002, 22, 225-250.
284. Liu, J.; Gong, T.; Wang, C.; Zhong, Z.; Zhang, Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization. Int. J. Pharm. 2007, 340, 153-162.
285. Issa, M.M.; Köping-Höggård, M.; Tommeraas, K.; Vårum, K.M.; Christensen, B.E.; Strand, S.P.; Artursson, P. Targeted gene delivery with trisaccharide-substituted chitosan oligomers in vitro and after lung administration in vivo. J. Control. Release 2006, 115, 103-112.
286. Ehrhardt, C.; Kneuer, C.; Bakowsky, U. Selectins-an emerging target for drug delivery. Adv. Drug Deliv. Rev. 2004, 56, 527-549.
287. Wang, J.; Kováč, P.; Sinaÿ, P.; Glaudemans, C.P.J. Synthetic C-oligosaccharides mimic their natural, analogous immunodeterminants in binding to three monoclonal immunoglobulins. Carbohydr. Res. 1998, 308, 191-193.
288. Machut-Binkowski, C.; Hapiot, F.; Cecchelli, R.; Martin, P.; Monflier, E. A versatile liposome/cyclodextrin supramolecular carrier for drug delivery through the blood-brain barrier. J. Incl. Phenom. Macrocycl. Chem. 2007, 57, 567-572.
289. Saad, M.; Garbuzenko, O.B.; Ber, E.; Chandna, P.; Khandare, J.J.; Pozharov, V.P.; Minko, T. Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging? J. Control. Release 2008, 130, 107-114.
290. Dziubla, T.D.; Shuvaev, V.V.; Hong, N.K.; Hawkins, B.J.; Madesh, M.; Takano, H.; Simone, E.; Nakada, M.T.; Fisher, A.; Albelda, S.M.; Muzykantov, V.R. Endothelial targeting of semipermeable polymer nanocarriers for enzyme therapies. Biomaterials 2008, 29, 215-227.
291. Leamon, C.P.; Reddy, J.A.; Vetzel, M.; Dorton, R.; Westrick, E.; Parker, N.; Wang, Y.; Vlahov, I. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res. 2008, 68, 9839-9844.
292. Zheng, Y.; Cai, Z.; Song, X.; Chen, Q.; Bi, Y.; Li, Y.; Hou, S. Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: In vitro studies. J. Drug Target. 2009, 17, 294-303.